139525-70-5

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
1(2H)-Quinolinecarboxylic acid, 6-bromo-3,4-dihydro-, methyl ester is used as a compound in pharmaceutical research and drug development for its potential biological activities. It is being investigated for its potential anti-inflammatory, analgesic, and antifungal properties, making it a promising candidate for the treatment of various diseases and conditions.
Used in Anti-inflammatory Applications:
In the medical industry, 1(2H)-Quinolinecarboxylic acid, 6-bromo-3,4-dihydro-, methyl ester is used as an anti-inflammatory agent for its potential to alleviate inflammation and related symptoms.
Used in Analgesic Applications:
In the pain management industry, 1(2H)-Quinolinecarboxylic acid, 6-bromo-3,4-dihydro-, methyl ester is used as an analgesic agent for its potential to relieve pain and discomfort.
Used in Antifungal Applications:
In the field of antifungal treatments, 1(2H)-Quinolinecarboxylic acid, 6-bromo-3,4-dihydro-, methyl ester is used as an antifungal agent for its potential to combat fungal infections and promote overall health.
Used in Disease Treatment:
1(2H)-Quinolinecarboxylic acid, 6-bromo-3,4-dihydro-, methyl ester is being investigated for its potential use in the treatment of various diseases and conditions, making it a valuable compound in the field of medicinal chemistry.

Upstream product

• 635-46-1 1,2,3,4-tetrahydroisoquinoline 
• 94567-78-9 3,4-dihydro-2H-quinoline-1-carboxylic acid methyl ester 

Downstream Products

• 1206965-53-8 tert-butyl (2-oxo-8-phenyl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-1(2H)-yl)acetate 
• 863724-39-4 (2-oxo-8-phenyl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-1(2H)-yl)acetic acid 

Relevant academic research and scientific papers

AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY

An amino pyrimidine compound for inhibiting protein tyrosine kinase activity, a pharmaceutical composition thereof, preparation therefor, and an application thereof. Specifically, an amino pyrimidine compound represented by formula (I), R1, R2, L, Y, R6, W, A, m, and n being defined in the specification, and a pharmaceutically acceptable salt, a stereoisomer, a solvent compound, a hydrate, a polymorphism, a prodrug, or an isotope variant thereof. The compound can be used for treating and/or preventing protein tyrosine kinase-related diseases such as cell proliferative diseases, cancers, and immune diseases.

Design, synthesis and structure-activity relationship of novel tricyclic benzimidazolone derivatives as potent 18 kDa translocator protein (TSPO) ligands

The 18 kDa translocator protein (TSPO) was identified as a discrete receptor for diazepam (1). Since TSPO in the central nervous system (CNS) is believed to regulate neurosteroids biosynthesis, selective TSPO ligands are expected to be useful in the treatment of psychiatric disorders. We synthesized three novel tricyclic benzimidazolone derivatives, and selected the dihydroimidazoquinolinone derivative 27 as a lead TSPO ligand. Study of the structure-activity relationship (SAR) of dihydroimidazoquinolinone derivatives revealed compounds with potent affinity for TSPO (subnanomolar Ki values), but poor metabolic stability. The optimization of these compounds led to compound 48 with potent affinity for TSPO and good in vitro PK profile.

NOVEL HETEROCYCLIC COMPOUND

A drug having a high affinity for benzodiazepine ω3 receptors and showing curative and preventive effects for anxiety and depression, which comprises as the active ingredient, for example, a compound of the formula (1): wherein R1 an